The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: Outcome of continuous glucose monitoring (CGM)

Acta Diabetologica

Volumn 49, Issue 1 SUPPL., 2012, Pages

  Sartore, Giovanni ^a   Chilelli, Nino Cristiano ^a   Burlina, Silvia ^a   Stefano, Paola Di ^b   Piarulli, Francesco ^a   Fedele, Domenico ^a   Mosca, Andrea ^c   Lapolla, Annunziata ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Elettronica SpA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Continuous glucose monitoring; Glucose variability; HbA1c; Hyperglycemia; Standard deviation

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; BLOOD; DRUG MONITORING; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878894191     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-012-0391-4     Document Type: Article

References (33)

1. DCCT Research Group (1993) The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin dependent diabetes mellitus. N Eng J Med 329:977-986
2. UK Prospective Diabetes Study group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patient with type 2 diabetes. Lancet 352:837-853
3. Dailey G (2007) Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A(1c) measurements. Mayo Clin Proc 82(2):229-235
4. Ceriello A, Ihnat MA (2010) 'Glycaemic variability': a new therapeutic challenge in diabetes and the critical care setting. Diabet Med 27(8):862-867
5. Ceriello A (2005) Postprandial hyperglycemia and diabetes complications. Is it time to treat? Diabetes 54:1-7
6. Kovatchev BP, Cox DJ, Farhy LS, Straume M, Gonder-Frederick L, Clarke WL (2000) Episodes of severe hypoglycemia in type 1 diabetes are preceded and followed within 48 hours by measurable disturbances in blood glucose. J Clin Endocrinol Metab 85:4287-4429
7. Kudva YC, Basu A, Jenkins GD, Pons GM, Vogelsang DA, Rizza RA, Smith SA, Isley WL (2007) Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin. Endocr Pract 13:244-250
8. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, for the A1c-Derived Average Glucose (ADAG) Study Group (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31(8):1473-1478
9. Siegelaar SE, Holleman F, Hoekstra JBL, DeVries JH (2010) Glucose variability, does it matter? Endocr Rev 31:171-182
10. Lee EY, Lee BW, Kim D, Lee YH, Kim KJ, Kang ES, Cha BS, Lee EJ, Lee HC (2011) Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2 diabetic patients. Acta Diabetol 48:167-172
11. Koga M, Saito H, Mukai M, Matsumoto S, Kasayama S (2010) Influence of iron metabolism indices on glycated haemoglobin but not glycated albumin levels in premenopausal women. Acta Diabetol 47:65-69
12. Koga M, Murai J, Saito H, Mukai M, Kasayama S (2010) Serum glycated albumin, but not glycated haemoglobin, is low in relation to glycemia in hyperuricemic men. Acta Diabetol 47:173-177
13. Koga M, Saito H, Mukai M, Otsuki M, Kasayama S (2009) Serum glycated albumin levels are influenced by smoking status, independent of plasma glucose levels. Acta Diabetol 46:141-144
14. Klonoff DC (2005) Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28:1231-1239
15. Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan D, Heine RJ, Nerup J, Borch-Johnsen K, Witte DR, the ADAG Study Group (2010) Associations between features of glucose exposure and HbA1c. The A1c-Derived Average Glucose (ADAG) study. Diabetes 59:1585-1590
16. Pickup JC, Kidd J, Burmiston S, Yemane N (2006) Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 22:232-237
17. Greven WL, Beulens JW, Biesma DH, Faiz S, de Valk HW (2010) Glycemic variability in inadequately controlled type 1 diabetes and type 2 diabetes on intensive insulin therapy: a cross-sectional, observational study. Diabetes Technol Ther 12:695-699
18. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295(14):1681-1687
19. Kohnert KD, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, Salzsieder E (2007) Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract 77:420-426
20. Rodbard D (2009) New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 11:551-565
21. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19:644-656
22. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ (2005) A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 7(2):253-263
23. Molnar GD, Taylor WF, Ho MM (1972) Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 8(5):342-348
24. McCall AL, Cox DJ, Crean J, Gloster M, Kovatchev BP (2006) A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther 8:644-653
25. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W (2006) Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 29:2433-2438
26. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke WL (2002) Methods for quantifying and monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabetes Technol Ther 4:295-303
27. Cox DJ, Kovatchev BP, Julian DM, Gonder-Frederick LA, Polonsky WH, Schlundt DG, Clarke WL (1994) Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab 79:1659-1662
28. UK Hypoglycemia Study Group (2007) Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50:1140-1147
29. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C, Owens DR (2010) Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 53:562-571
30. Rossetti P, Porcellati F, Fanelli CG, Perriello G, Torlone E, Bolli GB (2008) Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem 114(1):3-10
31. Monnier L, Colette C, Owens DR (2008) Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2:1094-1100
32. Nardacci EA, Bode BW, Hirsch IB (2010) Individualizing care for the many: the evolving role of professional continuous glucose monitoring systems in clinical practice. Diabetes Educ 36:4S-19S
33. Kilpatrick ES, Rigby AS, Atkin SL (2010) Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med 27:868-871